Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2020–2025

ROPES · ROles of ePitranscriptomic in diseasES

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2020-12-01 → 2025-05-31
Финансиране от ЕС
3 095 829 €
Участници
11
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Епитранскриптомът изследва модификации на РНК, като например m6A метилирането, които регулират работата на гените. Това помага за по-доброто разбиране на рака, заболяванията на стволовите клетки и имунната система, за да се открият нови терапевтични цели.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

ROles of ePitranscriptomic in diseasES

Epitranscriptomics is the study of RNA modifications that regulate gene expression beyond genetic sequences. This rapidly emerging field has great potential to transform our understanding of disease and identify novel therapeutic targets. Modifications such as RNA editing and m6A methylation are crucial, as they link genetic variation to specific cellular behaviours and diseases. In order to advance Europe’s capabilities in this critical research area, the ROPES project established a pioneering network of Early Stage Researchers (ESRs) to be trained at leading European academic and biotech institutions. ROPES specifically targeted three key disease areas in which epitranscriptomic changes play a significant role: (i) cancer, (ii) stem cell diseases, and (iii) disorders of the innate immune system. These areas were strategically chosen due to their significant societal impact and unmet medical needs. The project aimed to provide new scientific insights and therapeutic strategies by utilising the latest technological developments in RNA modification analysis. This would address Europe’s competitive disadvantage relative to the US and China in epitranscriptomics research.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Epitranscriptomics is the study of RNA modifications and their role in the regulation of gene expression. As happened for DNA, extensive covalent modification of RNA was found already in the 70s. Nevertheless, a spectacular expansion of epitranscriptomics occurred mostly in the past seven years, when an extensive layer of base decorations was discovered in mRNAs and shown to undergo cell modulation. These modifications produce programmable fluctuations in mRNA levels, translatability and subcellular compartmentalization, affecting primary cell programs such as cell differentiation and response to stress. We thus anticipate that RNA modifications will prove as important as chromatin dynamics in shaping cell phenotypes. This emerging field is hence crucial for both basic science and application to human disease. Epitranscriptomic would provide the missing link between genomic variability and cellular phenotypes, contributing to explaining the cause of specific diseases and developing novel therapies. Epitranscriptomic research is dominated by the US and China, with the EU lagging behind. We thus need to rapidly create a European framework to integrate and accelerate research efforts and industrial applications in this emerging field. To address this major European need, ROPES will train a group of Early Stage Researchers who will become the seed of the European epitranscriptome science of this decade. They will join a recently established network of academic research groups and biotech companies devoted to advancing our understanding of RNA modifications while promoting the development of new biomarkers and therapies. Focusing on RNA editing and m6A methylation, ROPES will investigate disease mechanisms and new therapies in the fields of cancer, stem cell diseases and innate immunity, while developing innovative epitranscriptomics methods. The ROPES European Training Network is the first European effort to tackle the epitranscriptome for the advancement of medicine.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз